The company's model is not AI drug discovery. Instead, they in-license assets that already have clinical data (Phase 1 or 2) and apply their AI platform to accelerate the drug development process. They identify development, not discovery, as the primary bottleneck in modern pharma.

Rather than inventing from scratch, InMedx licensed its advanced heart-rate variability algorithm from Omega Wave, a company serving pro sports teams. This allowed them to leverage a proven, precise technology and focus their resources on the higher-value activities of clinical validation and securing FDA clearance for medical use.

Elizabeth Jeffords shares a Genentech adage for biotech growth: give away your first and possibly second product via licensing deals. This strategy, which Iolyx followed, provides crucial non-dilutive capital and validation, building a foundation to eventually commercialize a third asset independently.

Syndax bypasses the lengthy initial lab phase by in-licensing promising science from external sources. This allows their internal experts to focus directly on clinical development in areas of high unmet medical need, a key strategy behind getting two drug approvals in two years.

Rahul Aras learned from his first venture that combining a novel target, a new modality (gene therapy), and a unique delivery device created too many unknowns. At Iterion, he prioritized minimizing such variables to create a more manageable risk profile for investors and partners, focusing on a single core innovation.

Tortugas Neuroscience's startup strategy focuses on in-licensing new chemical entities that have already cleared Phase 1, bypassing early toxicity and IND risks. Their criteria demand that each asset be extensible to multiple indications within CNS, creating operating leverage and maximizing the chances of success.

Eikon's acquisition strategy is guided by the "privileged owner" principle: only acquiring assets where they possess unique knowledge. For their lead drug, prior experience at Merck revealed a simple dosing change (from weight-based to body surface area) could solve the key toxicity issue, creating an opportunity that competitors missed.

Jade's strategy involves acquiring assets from Paragon, a company renowned for its protein engineering and half-life extension technology. This allows Jade to start with high-quality, potentially best-in-class antibody candidates without building the specialized discovery infrastructure in-house, accelerating its path to the clinic with a competitive advantage.

Ipsen avoids the high-risk, capital-intensive phase of basic research. Instead, its R&D strategy focuses on licensing promising drug candidates from universities and biotechs. The company then leverages its expertise in later-stage development, including toxicology, manufacturing scale-up (CMC), and clinical trials, to bring these de-risked assets to market.